Quantcast

Latest Atheroma Stories

2010-06-14 08:00:00

PLYMOUTH, Mich., June 14 /PRNewswire/ -- Esperion Therapeutics, a privately held biopharmaceutical company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the establishment of a collaborative research agreement with Cleveland Clinic, one of the world's leading academic medical centers. The collaboration will work to advance research targeting new HDL therapies to treat cardiovascular disease. The research will be led...

2010-05-28 14:05:01

NEJM authors: Physicians should consider this when tailoring treatment plans to beat stroke A published report provides the final details on how two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, though their effectiveness does vary by age, say researchers at the University of Alabama at Birmingham (UAB) School of Public Health in collaboration with other North American stroke investigators. In findings reported online in the New England...

2010-05-26 16:00:00

ABBOTT PARK, Ill., May 26 /PRNewswire-FirstCall/ -- Data from the CREST (Carotid Revascularization Endarterectomy vs. Stenting Trial) study were published today in The New England Journal of Medicine. In this trial, stenting and surgery had similar initial safety and longer-term outcomes for symptomatic and asymptomatic men and women. Adverse event rates of death, stroke and heart attack were also similar for both therapies. Abbott's ACCULINK® Carotid Stent System and...

2010-05-25 13:50:43

Researchers from Boston University School of Medicine (BUSM) have shown that use of magnetic resonance imaging (MRI) in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis. Rupture of vulnerable atherosclerotic plaque, which often occurs without prior symptoms, is responsible for a substantial number of deaths...

2010-05-14 09:49:28

Finding could lead to the development of new treatments for atherosclerosis Researchers at two laboratories at NYU Langone Medical Center have collaborated to identify a tiny micro-RNA, miR-33, that regulates key genes involved in cellular cholesterol transport. The study, published online May 13, 2010 in Science, found that inhibitors of miR-33 may be beneficial because they could enhance cholesterol removal from tissues and raise levels of HDL -- shown in clinical trials to promote...

2010-05-06 14:15:00

A new study by researchers at the Swedish medical university Karolinska Institutet shows that the immune defense's T cells can attack the "bad" LDL cholesterol and thereby cause an inflammation that leads to atherosclerosis. By producing a vaccine against the T cell receptors, the researchers have managed to inhibit the development of atherosclerosis in animals. The study is presented online in the distinguished periodical Journal of Experimental Medicine and is expected to be of considerable...

2010-04-29 08:29:52

Cholesterol crystals lead to life-threatening inflammation in blood vessel walls In addition to crystallized cholesterol, atherosclerotic plaques always contain large quantities of immune cells but, surprisingly, no bacteria or viruses. It was previously unclear just how the body's own defense forces are called into action. Even animals that are kept in an absolutely sterile environment can suffer from "clogging" or "furring" of the arteries when their food contains high levels of...

2010-04-09 14:00:00

TSX Exchange Symbol: RVX SAN FRANCISCO and CALGARY, April 9 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of RVX-208, the Company's lead drug, during the Atherosclerosis, Thrombosis, Vascular Biology (ATVB) conference being held in San Francisco, California. The presentation titled "RVX-208, an Orally Active Small Molecule, Raises ApoA-I...

2010-02-28 08:53:07

Two stroke-prevention procedures are safe and equally beneficial for men and women at risk for stroke, but the effectiveness does vary by age, say researchers at the University of Alabama at Birmingham (UAB) in collaboration with other North American stroke investigators. In findings reported Feb. 26 at the International Stroke Conference in San Antonio, Texas, the researchers say physicians now have better information when tailoring their treatment plans for patients at risk for stroke. The...

2010-02-25 13:00:00

Cleveland Clinic coordinates IVUS testing of RVX-208 in acute coronary syndrome patients CALGARY, Feb. 25 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related